Borealis Biosciences

Borealis Biosciences is the operator of a discovery-stage biotechnology company that aims to develop next-generation xrna-based kidney disease drugs. The company maps out target opportunities for subpopulations of kidney disease patients and defines methods to enhance the delivery of RNA drugs to specific cell types, enabling scientists to address significant unmet needs among kidney disease patients.